Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Greenwood Genetic Center Diagnostic Laboratories, |
RCV001806945 | SCV002051618 | likely pathogenic | not provided | 2021-03-05 | criteria provided, single submitter | clinical testing | PS2, PM2, PS3_Moderate, PP3, PP2 |
Gene |
RCV001806945 | SCV002583960 | uncertain significance | not provided | 2025-02-06 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 35904121) |
Labcorp Genetics |
RCV002542370 | SCV003025889 | uncertain significance | Tatton-Brown-Rahman overgrowth syndrome | 2024-05-16 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 292 of the DNMT3A protein (p.Ile292Thr). This variant is present in population databases (rs777306476, gnomAD 0.002%). This missense change has been observed in individual(s) with Tatton–Brown–Rahman syndrome (PMID: 35904121). ClinVar contains an entry for this variant (Variation ID: 1331601). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DNMT3A protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |